Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | NAMPT | P43490 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | FLT4 | P35916 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29128725 | 0.85 | RAB9A (0.59) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL9637653 | 0.83 | MEN1 (0.77) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL30051982 | 0.83 | MEN1 (0.77) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL30504811 | 0.83 | RAB9A (0.89) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL11213715 | 0.82 | RAB9A (0.72) | RAB9ANPC1PKMLMNAHIF1A | |
| Bromide SCHEMBL29417998 | 0.82 | MEN1 (0.74) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL967245 | 0.82 | RAB9A (0.72) | RAB9ANPC1PKMLMNAHIF1A | |
| Hydrochloric Acid SCHEMBL29388210 | 0.82 | MEN1 (0.74) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL6062650 | 0.82 | RAB9A (0.67) | RAB9ANPC1PKMLMNAHIF1A | |
| SCHEMBL6877095 | 0.80 | RAB9A (0.65) | RAB9ANPC1PKMLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651643-A4 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC (BM) | 2008-10-08 | — | — | EP | claimed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | claimed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | claimed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | claimed |
| EP-1651643-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2006-05-03 | — | — | EP | claimed |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | IRM LLC | 2005-09-08 | — | — | US | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| WO-2005011611-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2005-02-10 | — | — | WO | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-6794383-B2 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-09-21 | — | — | US | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-6436919-B1 | LOCAL ANESTHETICS THAT HAVE LONGER DURATION OF ACTION WHILE REDUCING UNDESIRED SIDE EFFECTS | THERAVANCE INC. | 2002-08-20 | — | — | US | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| EP-1216243-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | Advanced Medicine, Inc. (US) | 2002-06-26 | — | — | EP | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2001025234-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | ADVANCED MEDICINE, INC. (US) | 2001-04-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | RAB9A 698/4885NPC1 1345/4885PKM 3637/4885 |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | PDF, FDPS, DCTPP1 | RAB9A 2389/4885NPC1 1383/4885PKM 965/4885 |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | RAB9A 512/4885NPC1 37/4885PKM 4622/4885 |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | PDF, FDPS, DCTPP1 | RAB9A 1674/4885NPC1 761/4885PKM 1071/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | RAB9A 751/4885NPC1 1176/4885PKM 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.